RxDoctor Payments Data

Amanda McGee, NP

Gerontology · Rocky Mount, NCNPI 1538706841

Payments from drug & device makers

What this record shows

Livanova USA, Inc. accounts for 71.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $1,412, more than ten times the $76 reported in 2021.

$1,939in general payments, 2019–2025

Across 66 payments — averaging $29.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • AbbVie$360
  • Lilly USA, LLC$64
  • Dexcom, Inc.$25
  • Novo Nordisk$22
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21
  • plus $67 from 5 others

What the payments were for

  • Travel & lodging$1,11257%
  • Food & beverage$82743%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,939 in reported general payments places this provider in the 85th percentile of 165 gerontology providers in North Carolina.

See all gerontology providers in North Carolina

Medicare billing

Part B allowed, 2024
$87,509
Medicare patients
382
Services billed
1,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Rebif RebidoseInterferon Beta-1a/Albumin13$153,173
UbrelvyUbrogepant90$144,991
Nurtec OdtRimegepant Sulfate29$45,995
QuliptaAtogepant25$27,525
Aimovig AutoinjectorErenumab-Aooe29$26,445
Emgality PenGalcanezumab-Gnlm29$22,622
Levetiracetam510$17,751
Lacosamide106$9,928
Gabapentin545$9,216
Memantine Hcl379$8,662
DilantinPhenytoin Sodium Extended18$8,128
Memantine Hcl ErMemantine Hcl64$7,728
Carbamazepine ErCarbamazepine55$6,038
Pregabalin187$5,505
Donepezil Hcl572$4,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$360$172,516115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 165 gerontology providers in North Carolina.

Other gerontology in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →